OccuLogix, Inc.
NASDAQ : RHEO
TSX : RHE

OccuLogix, Inc.

July 18, 2005 10:52 ET

OccuLogix, Inc.: Positive PERC Data Presented at ASRS 2005 Annual Meeting

TORONTO, ONTARIO--(CCNMatthews - July 18, 2005) -

RheoNet Registry Also Updated

OccuLogix, Inc. (NASDAQ:RHEO)(TSX:RHE) announced that David Boyer, M.D., today presented Rheopheresis™ ("RHEO™") efficacy data from the Prospective Evaluation of Visual Functioning with Rheopheresis Treatment for Age-related Macular Degeneration in Canada ("PERC") protocol at the American Society of Retinal Specialists ("ASRS") Annual Meeting in Montreal, Quebec. Dr. Boyer is a clinical associate professor at the University of Southern California and an investigator in OccuLogix's pivotal (phase III) U.S. trial, MIRA-1.

PERC is a single center, prospective, study of RHEO™ treatment for intermediate-to-late stage Dry AMD. The study's principal investigator is retinal specialist David Wong, M.D., FRCSC. Co-investigators are Yoel Abells, M.D., Sanjive Jain, M.D., Kelly Wong, M.D., and Lorne Langer, M.D. Inclusion and exclusion criteria for patients entering PERC were similar to those entering MIRA-1, with the noted exception that PERC patients were not required to show elevated baseline concentrations of two out of three rheologic factors (a total serum cholesterol level of greater than or equal to 200 mg/dl, a serum fibrinogen level of greater than or equal to 300 mg/dl, or a serum immunoglobulin A (IGA) level greater than or equal to 200 mg/dl).

Dr. Boyer reported that of the 30 qualifying Dry AMD eyes studied in PERC, approximately 93% remained stable or improved at an average of 18 weeks post-baseline. Specifically:



- 3 (10%) gained greater than or equal to 3 lines of vision;
- 3 (10%) gained greater than or equal to 2 lines
but less than 3 lines of vision;
- 6 (20%) gained greater than or equal to 1 line
but less than 2 lines of vision;
- 3 (10%) gained more than 0 lines but less than 1 line of vision;
- 13 (43%) remained stable and showed no change of vision;
- 2 (7%) lost greater than or equal to 1 line of vision; and
- 0 (0%) lost greater than or equal to 2 lines of vision.


Dr. Boyer also reported the safety data from 4,766 reported RHEO™ treatments and the ophthalmologic data of 246 eyes of 169 Dry AMD patients from the RheoNet Registry, a collaborative effort between the Apheresis Research Institute in Cologne, Germany and OccuLogix in Canada. The registry contains a database of RHEO™ procedures from commercial centers and clinics in Germany and Canada.

Dr. Boyer's presentation at ASRS held that Rheopheresis™ can be regarded as a safe outpatient treatment for elderly patients with AMD and that the clinical outcomes recorded in both the PERC study and in the RheoNet Registry analysis have been consistent with other clinical trials, including the MIRA-1 interim analysis.

"We continue to be very encouraged by the consistency of the RHEO™ treatment results across studies, researchers and even continents," commented Elias Vamvakas, OccuLogix's Chairman and CEO. "I would like to thank all of the scientists like Drs. Wong and Boyer who have helped pioneer the RHEO procedure through their hard work and dedication," concluded Vamvakas.

About AMD

Age-related macular degeneration causes damage to the macula - the light-sensitive cells at the center of the retina at the back of the eye. The macula is responsible for our ability to see with enough detail to read, drive, watch television and perform other activities that require focused, straight-ahead vision, as well as providing information that allows us to perceive colors; thus, allowing one to maintain independence in daily activities.

There are two types of AMD - "dry", or non-exudative, and "wet", or exudative. Dry AMD, the most common form of the disease, currently afflicts approximately 13.0 to 13.5 million people in the United States, representing approximately 85% to 90% of all AMD cases in the country. Currently, there is no FDA-approved treatment for Dry AMD.

About the RHEO™ Procedure

The RHEO™ procedure consists of eight filtration treatments over a 10-12 week period. Each session is administered by a nurse and lasts approximately two to four hours. The patient's own blood circulates from one arm, through a dual-filter filtration system, and back to the body through the other arm. The RHEO™ procedure only requires that 10-12% of the patient's total blood volume circulate through the closed loop system at any given time.

Clinical studies suggest that RHEO™-filtered blood is able to flow more easily through even the tiniest capillaries in the body. Researchers believe that this improvement in microcirculation more effectively supplies the macular cells with oxygen and nutrients needed for proper function.

About OccuLogix, Inc.

OccuLogix is a health care company that brings innovative and evidenced-based medical therapies to market. OccuLogix's common shares trade on the NASDAQ National Market under the symbol 'RHEO' and on the Toronto Stock Exchange under the symbol 'RHE'.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian regulatory authorities, including our Registration Statement on Form S-1. We do not undertake to update any forward-looking statements.

Contact Information